Program
Valsartan
Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.
Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.
Drug pageValsartan: every studyMany companies study it; this page follows only the 125 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 1060 open or running | phase 4since Sep 10, 2005 | Nov 30, 2004 | none ahead |
| LG Chemits history only | 50 open or running | phase 3since Aug 5, 2013 | May 11, 2010 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since May 20, 2014 | May 20, 2014 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Jul 21, 2014 | Jul 21, 2014 | none ahead |
| ARKAY Therapeuticsits history only | 10 open or running | phase 2since Sep 23, 2018 | Sep 23, 2018 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Aug 3, 2015 | Aug 3, 2015 | none ahead |
| EMSits history only | 10 open or running | phase 3since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| Farma de Colombiaits history only | 10 open or running | phase 3since May 7, 2013 | May 7, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Aug 2, 2018 | Aug 2, 2018 | none ahead |
| JW Pharmaceuticalits history only | 10 open or running | phase 1since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Mar 4, 2025 | Mar 4, 2025 | Dec 2027phase 3 · NCT06863987 |
| TSH Biopharmits history only | 10 open or running | phase 4since Feb 4, 2014 | Feb 4, 2014 | none ahead |
| Yuhanits history only | 10 open or running | phase 1since Jan 5, 2012 | Jan 5, 2012 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Mar 16, 2006.
- Jul 20, 2010Phase 4 study in HypertensionNCT01167153 · 564 enrolled · China
- Nov 15, 2010Phase 4 study in Essential HypertensionNCT01241487 · 150 enrolled · Egypt
- Jan 20, 2011Phase 2 study in Isolated Systolic HypertensionNCT01281306 · 910 enrolled · United States, Argentina, Canada and more
- May 9, 2011Phase 3 study in HypertensionNCT01365481 · 150 enrolled · Colombia, Finland, Germany and more
- Aug 31, 2011Phase 1 study in HypertensionNCT01447485 · 12 enrolled · Japan
- Feb 23, 2012Phase 4 study in HypertensionNCT01541189 · 200 enrolled · China
- Jun 6, 2012Phase 3 study in HypertensionNCT01617681 · 127 enrolled · Belgium, Brazil, France and more
- Feb 12, 2014Phase 4 study in Essential HypertensionNCT02062645 · 115 enrolled · Turkey
- Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
- Dec 20, 2018Phase 3 study in Heart FailureNCT03785405 · 216 enrolled · United States, Argentina, Austria and more
- Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03988634 · 467 enrolled · United States, Canada
- Jul 10, 2019Phase 4 study in Chagas DiseaseNCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
- Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNCT04637555
- Nov 13, 2023Phase 3 study in Heart FailureNCT06149104 · 8 enrolled · Japan
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 106 Novartis leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06149104Heart Failure · Japan | 3 | Completed | Aug 14, 2024 | 8 |
| NCT04637555Post Myocardial Infarction | 3 | Withdrawn | Jun 1, 2023 | 0 |
| NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more | 4 | Completed | Mar 16, 2025 | 922 |
| NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada | 3 | Completed | Dec 14, 2022 | 467 |
| NCT03785405Heart Failure · United States, Argentina, Austria and more | 3 | Completed | Dec 29, 2023 | 216 |
| NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more | 3 | Completed | Oct 28, 2019 | 2,572 |
| NCT02062645Essential Hypertension · Turkey | 4 | Completed | Sep 2015 | 115 |
| NCT01617681Hypertension · Belgium, Brazil, France and more | 3 | Completed | Jan 24, 2017 | 127 |
| NCT01541189Hypertension · China | 4 | Completed | Jan 2013 | 200 |
| NCT01447485Hypertension · Japan | 1 | Completed | Oct 2011 | 12 |
| NCT01365481Hypertension · Colombia, Finland, Germany and more | 3 | Completed | Sep 2015 | 150 |
| NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more | 2 | Completed | Dec 2011 | 910 |
| NCT01241487Essential Hypertension · Egypt | 4 | Completed | Jan 2011 | 150 |
| NCT01167153Hypertension · China | 4 | Completed | Apr 2011 | 564 |
| NCT01001572Essential Hypertension | 3 | Completed | May 2010 | 932 |
| NCT00939588Hypertension · Russian Federation | 2 | Completed | Dec 2009 | 88 |
| NCT00931710Isolated Systolic Hypertension · United States | 4 | Completed | Jan 2010 | 488 |
| NCT00902304Hypertension · United States, Australia | 4 | Completed | Jul 2011 | 2,337 |
| NCT00821574Hypertension | 4 | Completed | Mar 2007 | 144 |
| NCT00809926Hypertension · United States | 4 | Completed | Jul 2009 | 451 |
| NCT00698646Hypertension · United States | 4 | Completed | Jun 2009 | 384 |
| NCT00699192Hypertension · Czech Republic, Finland, France and more | 3 | Completed | May 2009 | 965 |
| NCT00666536Hypertension · United States | 4 | Completed | Jan 2009 | 728 |
| NCT00687973Hypertension · France | 4 | Completed | Jan 2009 | 393 |
| NCT00700271Hypertension · France, Tunisia | 4 | Completed | Aug 2008 | 478 |
| NCT00550095Proteinuria · Egypt | 4 | Completed | Nov 2009 | 509 |
| NCT00548067Hypertension · India | 3 | Completed | 111 | |
| NCT00523744Hypertension · Germany | 3 | Completed | Dec 2007 | 257 |
| NCT00523549Hypertension · United States | 4 | Completed | Jan 2008 | 229 |
| NCT00487123Hypertension · Singapore | 4 | Completed | Sep 2007 | |
| NCT00457626Hypertension · United States, Belgium, Brazil and more | 3 | Completed | May 25, 2009 | 66 |
| NCT00446563Hypertension · Germany | 3 | Completed | Mar 2010 | 90 |
| NCT00446524Hypertension · Japan | 3 | Completed | Oct 2008 | 403 |
| NCT00446511Hypertension · United States, Belgium, France and more | 3 | Completed | Jun 2009 | 250 |
| NCT00439738Hypertension · United States | 4 | Completed | Nov 2007 | 412 |
| NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more | 3 | Completed | Nov 2007 | 1,183 |
| NCT00435162Hypertension · United States, Belgium, Brazil and more | 3 | Completed | Jan 2009 | 74 |
| NCT00433836Hypertension · United States, Belgium, France and more | 3 | Completed | Feb 2009 | 300 |
| NCT00426478Hypertension · Taiwan | 4 | Completed | 80 | |
| NCT00425997Hypertension · United States | 4 | Completed | Oct 2007 | 480 |
| NCT00425373Essential Hypertension · Japan | 3 | Completed | Mar 2008 | 1,474 |
| NCT00416728Hypertension · United States | 1 | Completed | 32 | |
| NCT00416468Hypertension · United States | 1 | Completed | 32 | |
| NCT00415883Healthy · India | 1 | Completed | 40 | |
| NCT00413413Hypertension · China | 3 | Completed | Nov 2007 | 1,134 |
| NCT00413049Hypertension · China | 3 | Completed | Nov 2007 | 698 |
| NCT00409851Hypertension · United States, Germany | 3 | Completed | Mar 2005 | 1,293 |
| NCT00409760Hypertension · Germany | 3 | Completed | Feb 2004 | 1,930 |
| NCT00409643Hypertension · United States, Germany | 3 | Completed | Jul 2004 | 1,259 |
| NCT00409578Myocardial Ischemia · United States, Belgium, Canada and more | 2 | Completed | Apr 2009 | 1,101 |
| NCT00400777Hypertension · Brazil | 4 | Completed | Nov 2007 | 460 |
| NCT00396656Hypertension · Germany, Switzerland | 3 | Completed | Dec 2007 | 30 |
| NCT00394745Hypertension · Germany, Switzerland | 3 | Completed | Jun 2007 | 45 |
| NCT00392262Hypertension · Germany, Switzerland | 3 | Completed | Feb 2007 | 224 |
| NCT00386607Hypertension · United States, Canada, Germany and more | 3 | Completed | Jul 2008 | 601 |
| NCT00385931Hypertension · United States | 3 | Completed | Apr 2003 | 412 |
| NCT00367939Hypertension · Germany | 3 | Completed | Jul 2006 | 132 |
| NCT00360178Hypertension · Germany, Switzerland | 3 | Completed | Dec 2006 | 198 |
| NCT00353912Hypertension · United States | 3 | Completed | Apr 2007 | 571 |
| NCT00351130Hypertension · Germany, Switzerland | 4 | Completed | Mar 2007 | 79 |
How it is read
Names in the registry
- “Valsartan”, 31 entries
- “valsartan”, 23 entries
- “sacubitril/valsartan”, 5 entries
- “valsartan plus hydrochlorothiazide”, 5 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 98 studies
- Essential Hypertension, 10 studies
- Heart Failure, 8 studies
- Diabetes Mellitus, Type 2, 5 studies
- Proteinuria, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.